Background {#Sec1}
==========

Viral hepatitis refers to a type of infectious disorder that is caused by hepatitis viruses which include HAV, HBV, HCV, HDV and HEV \[[@CR1], [@CR2]\]. In addition to acute liver injury, these hepatitis viruses may also lead to life-threatening conditions such as liver cirrhosis or hepatocellular carcinoma (HCC) \[[@CR3], [@CR4]\]. The clinical course of viral hepatitis is resulted from a complex interaction between pathogen, host and environmental factors, some patients may be asymptomatic the whole life, but some patients may eventually develop liver cirrhosis or even HCC \[[@CR5], [@CR6]\]. Therefore, there is no doubt that individual anti-viral immunity is vital for the onset and development of viral hepatitis.

Interleukin-10 (IL-10) serves as one of the most important anti-inflammatory and immunosuppressive factor, and it plays a crucial role in regulating anti-viral immune responses \[[@CR7]--[@CR9]\]. Considering the immune-regulatory effects of IL-10, over the last decade, investigators all over the world have repeatedly attempted to explore the relationships between polymorphisms in *IL*-*10* gene and the risk of viral hepatitis, yet the relationships between these polymorphisms and the risk of viral hepatitis are still inconclusive. So a meta-analysis was conducted to robustly analyze the relationships between polymorphisms in *IL*-*10* gene and the risk of viral hepatitis by integrating the results of previous works.

Methods {#Sec2}
=======

The PRISMA guideline was strictly followed by the authors when designing and implementing this study \[[@CR10]\].

Literature search and inclusion criteria {#Sec3}
----------------------------------------

Medline, Embase, Wanfang, VIP and CNKI were throughly searched by the authors with the below terms: (Interleukin-10 OR IL-10 OR Interleukin 10 OR IL 10) AND (Polymorphism OR Polymorphic OR Variation OR Variant OR Mutant OR Mutation OR SNP OR Genotypic OR Genotype OR Allelic OR Allele) AND (Viral hepatitis OR Chronic hepatitis OR Acute hepatitis OR Hepatitis A OR Hepatitis B OR Hepatitis C OR Hepatitis D OR Hepatitis E OR HAV OR HBV OR HCV OR HDV OR HEV). Moreover, we also manually screened the reference lists of retrieved publications to make up for the potential incompleteness of electronic literature searching.

Selection criteria of this meta-analysis were listed below: (1) Studies of case--control or cohort design; (2) Give genotypic or allelic frequencies of *IL*-*10* polymorphisms in cases with viral hepatitis and population-based controls; (3) The full manuscript with required genotypic or allelic frequencies of *IL*-*10* polymorphisms is retrievable or buyable. Articles would be excluded if one of the following three criteria is satisfied: (1) Studies without complete data about genotypic or allelic frequencies of *IL*-*10* polymorphisms in cases with viral hepatitis and population-based controls; (2) Narrative or systematic reviews, meta-analysis or comments; (3) Case series of subjects with viral hepatitis only. If duplicate publications were retrieved from literature search, we would only include the most complete one for integrated analyses.

Data extraction and quality assessment {#Sec4}
--------------------------------------

The authors extracted the following data items from eligible studies: (1) Last name of the leading author; (2) Publication year; (3) Country and ethnicity of study population; (4) The number of cases with viral hepatitis and population-based controls; (5) Genotypic frequencies of *IL*-*10* polymorphisms in cases with viral hepatitis and population-based controls. Hardy--Weinberg equilibrium was then tested by using genotypic frequencies of *IL*-*10* polymorphisms, and the threshold of derivation from HWE was set at 0.05. The quality of eligible publications was assessed by the Newcastle--Ottawa scale (NOS) \[[@CR11]\], and those with scores of 7--9 were considered to be publications of good quality. Two authors extracted data and assessed quality of eligible publications in parallel. A thorough discussion until a consensus is reached would be endorsed in case of any discrepancy between two authors.

Statistical analyses {#Sec5}
--------------------

All statistical analyses in this meta-analysis were performed by using the Cochrane Review Manager software. Relationships between *IL*-*10* gene polymorphisms and the risk of viral hepatitis were explored by using odds ratio and its 95% confidence interval. The statistically significant p value was set at 0.05. The authors used I^2^ statistics to evaluate heterogeneities among included studies. The authors would use DerSimonian--Laird method, which is also known as the random effect model, to integrate the results of eligible studies if I^2^ is larger than 50%. Otherwise, the authors would use Mantel--Haenszel method, which is also known as the fixed effect model, to integrate the results of eligible studies. Meanwhile, the authors also conduct subgroup analyses by ethnic groups and disease subtypes. Stabilities of integrated results were tested by deleting one eligible study each time, and then integrating the results of the rest of eligible studies. Publication biases were evaluated by assessing symmetry of funnel plots.

Results {#Sec6}
=======

Characteristics of included studies {#Sec7}
-----------------------------------

Three hundred and seventy-four literatures were retrieved by the authors by using our searching strategy. One hundred and thirty-nine literatures were then selected to screen for eligibility after omitting unrelated and repeated items. Six reviews and 48 case series were further excluded, and another nine literatures without all necessary genotypic or allelic data were further excluded by the authors. Totally 76 studies met the inclusion criteria, and were finally enrolled for integrated analyses (Fig. [1](#Fig1){ref-type="fig"}). Data extracted from eligible studies were summarized in Table [1](#Tab1){ref-type="table"} (Additional file [1](#MOESM1){ref-type="media"}).Fig. 1Flowchart of study selection for this meta-analysis. Systematic literature search of the present meta-analysisTable 1The characteristics of included studiesFirst author, yearCountryEthnicityType of diseaseSample size\
Case/controlGenotypes (wtwt/wtmt/mtmt)*p*-value for HWENOS scoreCasesControlsrs1800871 − 819 C/T Abbas 2009EgyptMixedHCV99/6244/43/1230/27/50.7527 Afzal 2011PakistanMixedHCV89/9916/66/715/81/3\< 0.0017 Barrett 2003IrelandCaucasianHCV92/6649/38/540/22/20.6217 Basturk 2008TurkeyCaucasianHBV50/6033/15/229/22/90.1757 Chen 2007ChinaAsianHCV72/18036/32/494/73/130.8197 Cheong 2006TaiwanAsianHBV261/72133/110/1835/30/70.8777 Chuang 2009TaiwanAsianHCV97/4647/38/1225/19/20.4917 Constantini 2002UKCaucasianHCV546/354NANANA7 Cunha 2018BrazilMixedHCV132/9859/54/1946/41/110.6857 Khan 2014IndiaMixedHCV150/15048/79/2357/75/180.3758 Komatsu 2014JapanAsianHBV52/5724/18/1025/22/100.1987 Kusumoto 2006JapanAsianHCV346/114156/160/3059/46/90.9947 Li 2006ChinaAsianHBV122/6355/52/1534/21/80.1188 Li 2015ChinaAsianHCV379/364176/167/36178/158/280.3838 Maurya 2018IndiaMixedViral hepatitis80/6045/29/648/10/20.1387 Miyazoe 2002JapanAsianHBV213/52153/56/438/13/10.9277 Moudi 2016IranMixedHBV221/20040/163/1830/162/8\<0.0018 Peng 2016ChinaAsianHBV173/18174/77/2286/78/170.9108 Pereira 2008BrazilMixedHCV128/9450/60/1836/48/100.3058 Persico 2006ItalyCaucasianHCV120/11060/54/653/51/60.1598 Qiu 2011ChinaAsianHBV381/359170/158/53181/143/350.3897 Ribeiro 2007BrazilMixedHBV30/4117/12/120/16/30.9357 Sepahi 2014IranMixedHCV66/6132/29/520/35/60.0997 Sodsai 2013ThailandAsianHBV131/14247/74/1067/59/160.5848 Sofian 2013IranMixedHBV64/3126/27/1116/11/40.3587 Srivastava 2014IndiaMixedHBV232/76111/75/4629/38/90.5177 Talaat 2014EgyptMixedHBV115/11969/40/662/52/50.1437 Tang 2012ChinaAsianHCV607/885259/286/62407/382/960.6538 Tang 2015ChinaAsianHBV207/56114/59/3425/17/140.0067 Vidigal 2002USAMixedHCV78/3653/16/920/13/30.6727 Wang 2012ChinaAsianHBV123/52540/66/17205/251/690.5677 Xie 2008ChinaAsianHBV186/15178/93/1573/68/100.2667 Yan 2009ChinaAsianHBV712/414334/291/87231/150/330.2198 Yee 2001USAMixedHCV49/5024/19/636/14/00.2507 Zein 2004USAMixedHCV58/8036/17/549/25/60.2797 Zhang 2006ChinaAsianHBV231/135103/103/2556/67/120.1998 Zhu 2015ChinaAsianHCV143/3656/66/2118/14/40.6167rs1800872 − 592 C/A Abbas 2009EgyptMixedHCV99/6244/43/1230/27/50.7527 Afzal 2011PakistanMixedHCV89/9916/66/715/81/3\<0.0017 Ahmadabadi 2012IranMixedHBV57/10031/24/242/55/30.0038 Barkhash 2017RussiaCaucasianHCV143/20380/52/11121/78/40.0327 Barrett 2003IrelandCaucasianHCV92/6649/38/540/22/20.6217 Basturk 2008TurkeyCaucasianHBV50/6033/15/229/22/90.1757 Cao 2016ChinaAsianHBV241/25488/104/49100/112/420.2677 Chen 2007ChinaAsianHCV72/18036/32/493/74/130.7417 Chen 2010ChinaAsianHBV304/361150/124/30173/145/430.1447 Cheong 2006TaiwanAsianHBV261/72133/110/1835/30/70.8777 Chuang 2009TaiwanAsianHCV143/13473/56/1465/59/100.4957 Constantini 2002UKCaucasianHCV546/354NANANA7 Falleti 2007ItalyCaucasianHCV50/9629/17/461/31/40.9807 Gao 2009ChinaAsianHBV69/7431/29/934/31/90.6417 Gao 2009ChinaAsianHCV55/7429/20/634/31/90.6417 Gao 2016ChinaAsianHBV180/8546/108/2626/31/180.0298 Jiang 2010ChinaAsianHBV169/11975/74/2051/56/120.5537 Jiang 2013ChinaAsianHBV250/13460/130/6040/62/320.4097 Jiang 2017ChinaAsianHBV136/28968/54/14144/115/300.3288 Karatayli 2014TurkeyCaucasianHBV116/5363/41/1229/20/40.8317 Khalil 2017EgyptMixedHCV100/12056/34/1052/60/80.0897 Komatsu 2014JapanAsianHBV52/5723/14/1526/21/100.1317 Kusumoto 2006JapanAsianHCV346/114156/160/3059/46/90.9947 Li 2003ChinaAsianHBV95/7624/58/1320/43/130.2187 Li 2006ChinaAsianHBV122/6355/52/1534/21/80.1198 Li 2015ChinaAsianHCV379/364176/167/36177/159/280.3458 Mangia 2004ItalyCaucasianHCV270/136156/90/2481/55/90.0037 Maurya 2018IndiaMixedViral hepatitis80/6026/46/836/22/20.5347 Miyazoe 2002JapanAsianHBV213/5295/91/2726/20/60.4837 Moudi 2016IranMixedHBV221/20036/168/1731/157/12\<0.0018 Oleksyk 2005USAMixedHCV856/398NANANA7 Peng 2006ChinaAsianHBV340/100178/130/3256/36/80.5197 Peng 2016ChinaAsianHBV173/18257/81/3579/81/220.8608 Pereira 2008BrazilMixedHCV128/9450/60/1836/48/100.3058 Persico 2006ItalyCaucasianHCV120/11060/54/653/51/60.1598 Qiu 2011ChinaAsianHBV721/359354/282/85181/143/350.3897 Ramos 2012BrazilMixedHCV161/1758/60/438/5/40.1207 Ren 2017ChinaAsianHBV250/13460/130/6040/62/320.4097 Ribeiro 2007BrazilMixedHBV30/4117/12/120/16/30.9357 Sepahi 2014IranMixedHCV66/6132/29/520/35/60.0997 Shaker 2012EgyptMixedHCV100/8035/33/3236/32/120.2807 Sheneef 2017EgyptMixedHCV100/5058/23/1925/15/100.0167 Silva 2015BrazilMixedHCV245/230106/110/29103/97/300.3478 Sodsai 2013ThailandAsianHBV131/14247/74/1067/59/160.5848 Sofian 2013IranMixedHBV86/3131/42/1316/11/40.3587 Srivastava 2014IndiaMixedHBV202/10671/102/2932/42/320.0337 Tang 2012ChinaAsianHCV623/905273/289/61429/370/1060.0588 Tseng 2006TaiwanAsianHBV344/184169/148/2790/75/190.5677 Vidigal 2002USAMixedHCV78/3653/16/923/10/30.2397 Wang 2008ChinaAsianHBV335/165132/169/3480/64/210.1567 Wang 2012ChinaAsianHBV123/52543/63/17206/250/690.6157 Wu 2010ChinaAsianHBV175/15382/67/2654/77/220.5157 Xiang 2014ChinaAsianHBV160/12456/70/3460/48/160.2037 Xie 2008ChinaAsianHBV186/15178/93/1573/68/100.2667 Yan 2009ChinaAsianHBV712/414334/291/87231/150/330.2198 Yee 2001USAMixedHCV49/5024/19/636/14/00.2507 Zein 2004USAMixedHCV52/8037/12/352/22/60.1117 Zhang 2006ChinaAsianHBV396/135189/168/3956/67/120.1998 Zhu 2015ChinaAsianHCV179/70574/80/25268/348/890.1427rs1800896 − 1082 G/A Abbas 2009EgyptMixedHCV99/6241/41/1723/30/90.8777 Afzal 2011PakistanMixedHCV89/9915/67/74/92/3\<0.0017 Barrett 2003IrelandCaucasianHCV92/6620/47/2520/36/100.3447 Basturk 2008TurkeyCaucasianHBV50/6017/22/1138/16/60.0497 Bouzgarrou 2009TunisiaMixedHCV100/10338/43/1942/49/120.6877 Cao 2016ChinaAsianHBV241/25488/112/41116/111/270.9547 Chen 2007ChinaAsianHCV72/18070/2/0176/4/00.8807 Chen 2010ChinaAsianHBV304/361264/37/3319/40/20.5447 Cheong 2006TaiwanAsianHBV261/204225/35/1173/29/20.5317 Chuang 2009TaiwanAsianHCV143/133132/11/0124/9/00.6867 Conde 2013BrazilMixedHBV53/9727/20/647/41/90.9897 Constantini 2002UKCaucasianHCV546/354NANANA7 Cunha 2018BrazilMixedHCV132/9856/54/2244/38/160.1247 Dogra 2011IndiaMixedHCV70/7038/22/1042/25/30.7647 Falleti 2007ItalyCaucasianHCV50/9617/25/828/43/250.3127 Gao 2009ChinaAsianHBV69/7442/27/057/16/10.9187 Gao 2009ChinaAsianHCV55/7432/21/257/16/10.9187 Gao 2016ChinaAsianHBV190/81177/12/163/18/00.2618 Gao 2017ChinaAsianHBV + HCV179/74109/68/257/16/10.9187 Helal 2014EgyptMixedHCV50/5022/19/918/24/81.0007 Jiang 2013ChinaAsianHBV250/134189/58/3102/26/60.0197 Karatayli 2014TurkeyCaucasianHBV161/5148/86/2724/25/20.1447 Khan 2014IndiaMixedHCV150/15064/67/1985/55/100.7858 Knapp 2003UKCaucasianHCV577/94183/250/14427/54/130.0907 Kusumoto 2006JapanAsianHCV346/114316/30/0103/11/00.5887 Li 2006ChinaAsianHBV62/6348/14/052/11/00.4488 Li 2015ChinaAsianHCV379/364323/54/2310/51/30.5778 Lio 2003ItalyCaucasianHCV60/13527/15/1834/86/15\<0.00017 Liu 2010ChinaAsianHBV513/187416/88/9160/24/30.0757 Mangia 2004ItalyCaucasianHCV270/145120/110/4056/66/230.6317 Maurya 2018IndiaMixedVral hepatitis80/6065/13/246/12/20.2977 Minton 2005UKCaucasianHBV284/5477/123/8418/25/110.6697 Miyazoe 2002JapanAsianHBV213/52201/10/248/4/00.7737 Moudi 2016IranMixedHBV221/20072/118/31100/84/160.7788 Oleksyk 2005USAMixedHCV856/398NANANA7 Pár 2014IndiaMixedHCV672/92214/333/12548/32/120.0878 Pasha 2013EgyptMixedHCV440/220396/44/0193/27/00.3328 Peng 2006ChinaAsianHBV340/100314/23/395/5/00.7987 Peng 2016ChinaAsianHBV173/18283/74/1696/74/120.6538 Pereira 2008BrazilMixedHCV128/9456/55/1738/43/130.8818 Persico 2006ItalyCaucasianHCV120/11043/51/2636/56/180.6288 Ren 2017ChinaAsianHBV250/134189/58/3102/26/60.0197 Ribeiro 2007HBVMixedHBV30/4112/16/216/20/50.7437 Sepahi 2014IranMixedHCV50/5020/15/1539/6/5\<0.0017 Sheneef 2017EgyptMixedHCV100/5026/43/3110/35/50.0037 Silva 2015BrazilMixedHCV245/230106/110/29119/83/280.0298 Sodsai 2013ThailandAsianHBV130/142116/13/1125/17/00.4488 Sofian 2013IranMixedHBV66/3132/27/713/15/30.6557 Srivastava 2014IndiaMixedHBV232/7696/73/6332/43/10.0027 Talaat 2014EgyptMixedHBV115/11932/53/3043/61/150.3527 Tang 2012ChinaAsianHCV626/914552/74/0791/123/00.0298 Truelove 2008USAMixedHBV45/7615/24/638/32/60.8377 Vidigal 2002USAMixedHCV78/3629/22/2716/14/60.3467 Wu 2010ChinaAsianHBV175/153148/27/0122/30/10.5617 Xie 2008ChinaAsianHBV186/151164/22/0128/22/10.9597 Yan 2009ChinaAsianHBV732/414644/68/0389/25/00.5268 Yao 2015ChinaAsianHBV318/318125/141/52152/135/310.8987 Zein 2004USAMixedHCV52/8017/18/1728/32/200.0877 Zhang 2006ChinaAsianHBV396/135335/61/0119/16/00.4648 Zhu 2005ChinaAsianHBV167/123115/45/781/37/50.7667*HBV* hepatitis B virus infection, *HCV* hepatitis C virus infection, *wt* wild type, *mt* mutant type, *HWE* Hardy--Weinberg equilibrium, *NOS* Newcastle--ottawa scale, *NA* not available

Integrated analyses for rs1800871 polymorphism and the risk of viral hepatitis {#Sec8}
------------------------------------------------------------------------------

Thirty-seven eligible literatures assess the relationship between rs1800871 polymorphism and the risk of viral hepatitis. The integrated analyses demonstrated that rs1800871 polymorphism was significantly associated with the risk of viral hepatitis in overall population (dominant comparison: OR = 0.89, p = 0.002; recessive comparison: OR = 1.21, p = 0.004; allele comparison: OR = 0.90, p = 0.0004) and Asians (dominant comparison: OR = 0.84, p = 0.0001; over-dominant comparison: OR = 1.14, p = 0.005; allele comparison: OR = 0.88, p = 0.0002), but not in Caucasians. Further analyses by disease subtypes revealed similar positive results for rs1800871 polymorphism in both HBV and HCV subgroups (see Table [2](#Tab2){ref-type="table"}).Table 2Meta-analyses results of *IL*-*10* gene polymorphisms and viral hepatitisVariablesSample sizeDominant comparisonRecessive comparisonOver-dominant comparisonAllele comparison*p* valueOR (95% CI)I^2^ statistic (%)*p* valueOR (95% CI)I^2^ statistic (%)*p* valueOR (95% CI)I^2^ statistic (%)*p* valueOR (95% CI)I^2^ statistic (%)rs1800871 − 819 C/T Overall6835/5679*0.0020.89 (0.82--0.96)*28*0.0041.21 (1.06--1.38)*00.171.06 (0.98--1.14)24*0.00040.90 (0.85--0.95)*27 Asian4436/3832*0.00010.84 (0.76--0.92)*00.091.14 (0.98--1.33)0*0.0051.14 (1.04--1.25)*0*0.00020.88 (0.82--0.94)*0 Caucasian808/5900.631.13 (0.67--1.91)510.370.71 (0.33--1.51)390.931.02 (0.71--1.46)00.481.19 (0.73--1.93)62 HBV3504/27340.050.90 (0.80--1.00)38*0.031.21 (1.02--1.45)*90.511.04 (0.93--1.16)36*0.020.91 (0.84-0.98)*37 HCV3251/28850.050.89 (0.80--1.00)00.071.20 (0.99--1.45)00.361.05 (0.94--1.18)0*0.030.91 (0.83--0.99)*0rs1800872 − 592 C/A Overall12121/9873*0.0030.91 (0.86-0.97)*250.061.09 (1.00--1.20)130.071.06 (0.99--1.12)30*0.0030.93 (0.89--0.98)*34 Asian7935/6880*0.00090.89 (0.83--0.95)*90.201.07 (0.96--1.19)0*0.0071.10 (1.03--1.18)*29*0.0040.93 (0.88--0.98)*8 Caucasian1387/10780.700.96 (0.78--1.18)00.151.36 (0.89--2.08)340.390.91 (0.74--1.13)00.190.89 (0.76--1.06)41 HBV6900/4995*0.0080.90 (0.83--0.97)*260.431.05 (0.93--1.18)19*0.021.10 (1.02--1.19)*31*0.040.94 (0.89--1.00)*39 HCV5141/48180.350.96 (0.87--1.05)1*0.051.17 (1.00--1.37)*10.640.98 (0.89--1.08)120.080.94 (0.87--1.01)14rs1800896 − 1082 G/A Overall13133/8862*0.020.87 (0.78--0.98)*57*\<0.00011.60 (1.41--1.82)*260.560.96 (0.85--1.09)60*\<0.00010.83 (0.76--0.90)*55 Asian6452/4797*0.020.88 (0.79--0.98)*490.481.12 (0.82--1.53)00.111.09 (0.98--1.22)400.190.90 (0.77--1.05)54 Caucasian2210/11650.650.92 (0.64--1.32)69*0.0091.67 (1.14--2.46)*540.220.80 (0.55--1.15)72*0.030.78 (0.62--0.98)*64 HBV6227/4067*0.010.82 (0.70-0.96)*51\< *0.00011.73 (1.42--2.10)*270.611.04 (0.89--1.21)51*0.0020.81 (0.71--0.93)*57 HCV6647/46610.520.94 (0.79--1.13)60\< *0.00011.52 (1.29--1.80)*330.140.87 (0.71--1.05)66*0.0080.85 (0.75--0.96)*51The values in italic represent there is statistically significant differences between cases and controls*HBV* Hepatitis B virus infection, *HCV* Hepatitis C virus infection, *OR* Odds ratio, *CI* Confidence interval, *NA* Not available

Integrated analyses for rs1800872 polymorphism and the risk of viral hepatitis {#Sec9}
------------------------------------------------------------------------------

Fifty-eight eligible literatures assessed the relationship between rs1800872 polymorphism and the risk of viral hepatitis. The integrated analyses demonstrated that rs1800872 polymorphism was significantly associated with the risk of viral hepatitis in overall population (dominant comparison: OR = 0.91, p = 0.003; allele comparison: OR = 0.93, p = 0.003) and Asians (dominant comparison: OR = 0.89, p = 0.0009; over-dominant comparison: OR = 1.10, p = 0.007; allele comparison: OR = 0.93, p = 0.004), but not in Caucasians. Further analyses by disease subtypes revealed similar positive results for rs1800871 polymorphism in both HBV and HCV subgroups (see Table [2](#Tab2){ref-type="table"}).

Integrated analyses for rs1800896 polymorphism and the risk of viral hepatitis {#Sec10}
------------------------------------------------------------------------------

Fifty-nine eligible literatures assessed the relationship between rs1800896 polymorphism and the risk of viral hepatitis. The integrated analyses demonstrated that rs1800896 polymorphism was significantly associated with the risk of viral hepatitis in overall population (dominant comparison: OR = 0.87, p = 0.02; recessive comparison: OR = 1.60, p \< 0.0001; allele comparison: OR = 0.83, p \< 0.0001), Asians (dominant comparison: OR = 0.88, p = 0.02) and Caucasians (recessive comparison: OR = 1.67, p = 0.009; allele comparison: OR = 0.78, p = 0.03). Further analyses by disease subtypes revealed similar positive results for rs1800871 polymorphism in both HBV and HCV subgroups (see Table [2](#Tab2){ref-type="table"}).

Sensitivity analyses {#Sec11}
--------------------

The authors examined stabilities of integrated analyses results by deleting studies that violated HWE, and then integrating the results of the rest of studies. The trends of associations were not significantly altered in sensitivity analyses, which indicated that from statistical perspective, our integrated analyses results were reliable and stable.

Publication biases {#Sec12}
------------------

The authors examined potential publication biases in this meta-analysis by assessing symmetry of funnel plots. Funnel plots were found to be overall symmetrical, which indicated that our integrated analyses results were not likely to be severely deteriorated by publication biases.

Discussion {#Sec13}
==========

This meta-analysis, for the first time, robustly assessed associations between polymorphisms in *IL*-*10* gene and the risk of viral hepatitis. The integrated analyses results demonstrated that rs1800871 (− 819 C/T), rs1800872 (− 592 C/A) and rs1800896 (− 1082 G/A) polymorphisms were all significantly associated with the risk of viral hepatitis in Asians, whereas only rs1800896 (− 1082 G/A) polymorphism was significantly associated with the risk of viral hepatitis in Caucasians. In further analyses by disease subtypes, we noticed that the three investigated polymorphisms were all significantly associated with the risk of both HBV and HCV.

The following three points should be considered when interpreting our integrated findings. First, based on the findings of previous observational studies, it is believed that the three investigated *IL*-*10* polymorphisms may alter mRNA expression level of *IL*-*10* gene, impact anti-viral immune responses, and then influence the risk of viral hepatitis \[[@CR12], [@CR13]\]. Nevertheless, it should be noted that future experimental studies are still required to reveal the exact molecular mechanisms underlying the observed positive findings of this meta-analysis. Second, we wish to study all polymorphic loci of *IL*-*10* gene. However, our comprehensive literature searching did not reveal sufficient eligible literatures to warrant integrated analyses for other polymorphic loci of *IL*-*10* gene, so we only assessed associations with the risk of viral hepatitis for the three most commonly investigated polymorphisms of *IL*-*10* gene in this meta-analysis. Third, although we aimed to investigate all subtypes of viral hepatitis in this meta-analysis, it is worth noting that the majority of eligible studies were about HBV or HCV. So future studies should continue to explore associations between polymorphisms in *IL*-*10* gene and the risk of other subtypes of viral hepatitis.

The three major limitations of our integrated analyses were listed below. Firstly, our integrated analyses results were only derived from unadjusted pooling of previous works. Without access to raw data of eligible studies, we can only estimate associations based on re-calculations of raw genotypic frequencies, but we have to admit that lack of further adjustment for baseline characteristics may certainly impact reliability of our findings \[[@CR14]\]. Secondly, environmental factors may also affect relationships between polymorphisms in *IL*-*10* gene and the risk of viral hepatitis. However, most of the authors only paid attention to genetic associations in their publications, so it is impossible for us to explore genetic-environmental interactions in a meta-analysis based on these previous publications \[[@CR15]\]. Thirdly, we did not enroll grey literatures for integrated analyses because these literatures are always incomplete and it is impossible for us to extract all required data items from these literatures or assess their quality through the NOS scale. Nevertheless, considering that we did not include grey literatures for integrated analyses, despite that funnel plots were found to be overall symmetrical, it should be acknowledged that publication biases still may affect the robustness of our integrated analyses results \[[@CR16]\].

Conclusion {#Sec14}
==========

In conclusion, this meta-analysis demonstrates that rs1800871 (− 819 C/T), rs1800872 (− 592 C/A) and rs1800896 (− 1082 G/A) polymorphisms may influence the risk of viral hepatitis in Asians, while only rs1800896 (− 1082 G/A) polymorphism may influence the risk of viral hepatitis in Caucasians. In further analyses by disease subtypes, we noticed that the three investigated polymorphisms may influence the risk of both HBV and HCV. However, future studies should continue to investigate associations between polymorphisms in *IL*-*10* gene and the risk of other subtypes of viral hepatitis.
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HBV
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:   Interleukin-10
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